Harnessing dendritic cells in cancer

Seminars in Immunology

Volumn 23, Issue 1, 2011, Pages 42-49

  Apetoh, Lionel ^a,b,c   Locher, Clara ^d,e,f   Ghiringhelli, François ^a,b,c   Kroemer, Guido ^e,g,h,i,j   Zitvogel, Laurence ^d,e,f  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d University Paris XI   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g INSERM   (France)

^h CENTRE DE RECHERCHE DES CORDELIERS   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Adaptive immunity; Anticancer immunity; Dendritic cells; Immunomodulation; Innate immunity; T cells

Indexed keywords

ANTIBODY CONJUGATE; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN RECEPTOR; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; INTERFERON; OXALIPLATIN; PACLITAXEL; PROSTAGLANDIN E2; PROSTAGLANDIN INHIBITOR; RAG2 PROTEIN; RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; APOPTOSIS; BRONCHUS ASSOCIATED LYMPHOID TISSUE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER THERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL SECRETION; CELL SURVIVAL; CELL THERAPY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG APPROVAL; ENDOTHELIUM CELL; EXOSOME; FIBROBLAST; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; LYMPHOCYTE; LYMPHOID ORGANOGENESIS; LYMPHOID TISSUE; MACROPHAGE; MOLECULAR INTERACTION; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; ORGANOGENESIS; PHAGOCYTOSIS; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TARGET CELL; TUMOR CELL; TUMOR INFILTRATING DENDRITIC CELL; TUMOR MICROENVIRONMENT; VIRUS INFECTION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 79952444232     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2011.01.003     Document Type: Review

References (102)

1. Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L.H., et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 2003, 198:433-442.
2. Borg C., Terme M., Taieb J., Menard C., Flament C., Robert C., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004, 114:379-388.
3. Smyth M.J., Godfrey D.I., Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001, 2:293-299.
4. + dendritic cells in cytotoxic T cell immunity. Science 2008, 322:1097-1100.
5. Crowe N.Y., Smyth M.J., Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002, 196:119-127.
6. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
7. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
8. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
9. Chaput N., Conforti R., Viaud S., Spatz A., Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008, 27:5920-5931.
10. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
11. Picaud S., Bardot B., De Maeyer E., Seif I. Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 2002, 22:457-462.
12. Hartmann E., Wollenberg B., Rothenfusser S., Wagner M., Wellisch D., Mack B., et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003, 63:6478-6487.
13. Cao W., Bover L., Cho M., Wen X., Hanabuchi S., Bao M., et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 2009, 206:1603-1614.
14. Cao W., Rosen D.B., Ito T., Bover L., Bao M., Watanabe G., et al. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J Exp Med 2006, 203:1399-1405.
15. Cho M., Ishida K., Chen J., Ohkawa J., Chen W., Namiki S., et al. SAGE library screening reveals ILT7 as a specific plasmacytoid dendritic cell marker that regulates type I IFN production. Int Immunol 2008, 20:155-164.
16. Novitskiy S.V., Ryzhov S., Zaynagetdinov R., Goldstein A.E., Huang Y., Tikhomirov O.Y., et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 2008, 112:1822-1831.
17. Pardoll D., Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004, 10:887-892.
18. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321.
19. Cheng F., Wang H.W., Cuenca A., Huang M., Ghansah T., Brayer J., et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19:425-436.
20. + T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res 2008, 68:7520-7529.
21. Yang L., Yamagata N., Yadav R., Brandon S., Courtney R.L., Morrow J.D., et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003, 111:727-735.
22. von Bergwelt-Baildon M.S., Popov A., Saric T., Chemnitz J., Classen S., Stoffel M.S., et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006, 108:228-237.
23. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008, 205:2235-2249.
24. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010, 120:457-471.
25. Villablanca E.J., Raccosta L., Zhou D., Fontana R., Maggioni D., Negro A., et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med 2010, 16:98-105.
26. Herber D.L., Cao W., Nefedova Y., Novitskiy S.V., Nagaraj S., Tyurin V.A., et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 2010, 16:880-886.
27. GeurtsvanKessel C.H., Willart M.A., Bergen I.M., van Rijt L.S., Muskens F., Elewaut D., et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med 2009, 206:2339-2349.
28. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008, 26:4410-4417.
29. Lee Y., Chin R.K., Christiansen P., Sun Y., Tumanov A.V., Wang J., et al. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 2006, 25:499-509.
30. Thompson E.D., Enriquez H.L., Fu Y.X., Engelhard V.H. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010, 207:1791-1804.
31. Shields J.D., Kourtis I.C., Tomei A.A., Roberts J.M., Swartz M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
32. Janssen E., Tabeta K., Barnes M.J., Rutschmann S., McBride S., Bahjat K.S., et al. Efficient T cell activation via a toll-interleukin 1 receptor-independent pathway. Immunity 2006, 24:787-799.
33. Krebs P., Barnes M.J., Lampe K., Whitley K., Bahjat K.S., Beutler B., et al. NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood 2009, 113:6593-6602.
34. Levitsky H.I., Lazenby A., Hayashi R.J., Pardoll D.M. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994, 179:1215-1224.
35. Mocikat R., Braumuller H., Gumy A., Egeter O., Ziegler H., Reusch U., et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003, 19:561-569.
36. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413:165-171.
37. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002, 3:83-90.
38. Brandt C.S., Baratin M., Yi E.C., Kennedy J., Gao Z., Fox B., et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009, 206:1495-1503.
39. Messi M., Giacchetto I., Nagata K., Lanzavecchia A., Natoli G., Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 2003, 4:78-86.
40. Vitale M., Della Chiesa M., Carlomagno S., Pende D., Arico M., Moretta L., et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005, 106:566-571.
41. Morandi B., Bougras G., Muller W.A., Ferlazzo G., Munz C. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol 2006, 36:2394-2400.
42. Kalinski P., Giermasz A., Nakamura Y., Basse P., Storkus W.J., Kirkwood J.M., et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 2005, 42:535-539.
43. + T-cell-independent pathway for antitumor CTL induction. Blood 2005, 106:338-344.
44. Andrews D.M., Estcourt M.J., Andoniou C.E., Wikstrom M.E., Khong A., Voigt V., et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med 2010, 207:1333-1343.
45. Fujii S., Liu K., Smith C., Bonito A.J., Steinman R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004, 199:1607-1618.
46. Semmling V., Lukacs-Kornek V., Thaiss C.A., Quast T., Hochheiser K., Panzer U., et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 2010, 11:313-320.
47. Taieb J., Chaput N., Menard C., Apetoh L., Ullrich E., Bonmort M., et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006, 12:214-219.
48. Ullrich E., Bonmort M., Mignot G., Jacobs B., Bosisio D., Sozzani S., et al. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J Immunol 2008, 180:7887-7897.
49. + subset and are licensed by tumor cells. Cancer Res 2009, 69:6590-6597.
50. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
51. Dunn G.P., Bruce A.T., Sheehan K.C., Shankaran V., Uppaluri R., Bui J.D., et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005, 6:722-729.
52. Sancho D., Joffre O.P., Keller A.M., Rogers N.C., Martinez D., Hernanz-Falcon P., et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009, 458:899-903.
53. + dendritic cells. J Exp Med 2010, 207:1261-1271.
54. + dendritic cells. J Exp Med 2010, 207:1283-1292.
55. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010, 207:1247-1260.
56. Contreras V., Urien C., Guiton R., Alexandre Y., Vu Manh T.P., Andrieu T., et al. Existence of CD8{alpha}-like dendritic cells with a conserved functional specialization and a common molecular signature in distant mammalian species. J Immunol 2010, 185:3313-3325.
57. Lin M.L., Zhan Y., Villadangos J.A., Lew A.M. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol 2008, 86:353-362.
58. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666.
59. Zammit D.J., Cauley L.S., Pham Q.M., Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005, 22:561-570.
60. + T cells in response to viral infections of the lung and skin. Eur J Immunol 2006, 36:327-335.
61. + DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol 2010, 40:1617-1627.
62. + T cells. Nat Immunol 2007, 8:1060-1066.
63. Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo L.D., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995, 1:1297-1302.
64. Zitvogel L., Mayordomo J.I., Tjandrawan T., DeLeo A.B., Clarke M.R., Lotze M.T., et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996, 183:87-97.
65. Fernandez N.C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999, 5:405-411.
66. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998, 4:594-600.
67. Shimizu K., Kurosawa Y., Taniguchi M., Steinman R.M., Fujii S. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007, 204:2641-2653.
68. Ali O.A., Emerich D., Dranoff G., Mooney D.J. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med 2009, 1(8):ra19.
69. Trinite B., Voisine C., Yagita H., Josien R. A subset of cytolytic dendritic cells in rat. J Immunol 2000, 165:4202-4208.
70. + rat dendritic cells induce rapid caspase-independent apoptosis-like cell death in various tumor and nontumor cells and phagocytose their victims. J Immunol 2005, 175:2408-2417.
71. Alli R., Savithri B., Das S., Varalakshmi C., Rangaraj N., Khar A. Involvement of NKR-P2/NKG2D in DC-mediated killing of tumor targets: indicative of a common, innate, target-recognition paradigm?. Eur J Immunol 2004, 34:1119-1126.
72. Chan C.W., Crafton E., Fan H.N., Flook J., Yoshimura K., Skarica M., et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006, 12:207-213.
73. + Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest 2008, 118:3751-3761.
74. Tsuji S., Matsumoto M., Takeuchi O., Akira S., Azuma I., Hayashi A., et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 2000, 68:6883-6890.
75. Lee J.C., Lee K.M., Kim D.W., Heo D.S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004, 172:7335-7340.
76. + regulatory T cell proliferation. J Exp Med 2005, 202:919-929.
77. + T cells by exogenous cell-associated antigens. Immunity 2002, 17:211-220.
78. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
79. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61.
80. Apetoh L., Ghiringhelli F., Tesniere A., Criollo A., Ortiz C., Lidereau R., et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007, 220:47-59.
81. Apetoh L., Mignot G., Panaretakis T., Kroemer G., Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 2008, 14:141-151.
82. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
83. Sluyter R., Shemon A.N., Wiley J.S. Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J Immunol 2004, 172:3399-3405.
84. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H.I., Antonia S., et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2009, 120:1111-1124.
85. Taieb J., Chaput N., Schartz N., Roux S., Novault S., Menard C., et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006, 176:2722-2729.
86. Nowak A.K., Lake R.A., Marzo A.L., Scott B., Heath W.R., Collins E.J., et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003, 170:4905-4913.
87. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010, 70:3052-3061.
88. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
89. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517-1526.
90. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332.
91. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999, 190:1669-1678.
92. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001, 98:8809-8814.
93. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., Lyerly H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999, 59:56-58.
94. de Vries I.J., Lesterhuis W.J., Barentsz J.O., Verdijk P., van Krieken J.H., Boerman O.C., et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005, 23:1407-1413.
95. Kantoff P.W., Higano C.S., Shore N.D., Roy Berger E., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
96. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002, 196:1627-1638.
97. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824.
98. Birkholz K., Schwenkert M., Kellner C., Gross S., Fey G., Schuler-Thurner B., et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 2010, 116:2277-2285.
99. + T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010, 116:1685-1697.
100. + dermal dendritic cells. Immunity 2008, 29:497-510.
101. Idoyaga J., Cheong C., Suda K., Suda N., Kim J.Y., Lee H., et al. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol 2008, 180:3647-3650.
102. Manicassamy S., Ravindran R., Deng J., Oluoch H., Denning T.L., Kasturi S.P., et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med 2009, 15:401-409.